Assistant Professor of Oncology and Medicine
Contact Information:
New Patients: 410-955-8964
Return Patients: 410-955-8893
Administrative Office: 410-955-8839
fax: 410-955-0960
Clinical/Academic Interests:
Hodgkin’s lymphoma, aggressive non-Hodgkin’s lymphomas, tumor stem cell therapies
Research Interests:
Dr. Kasamon is a clinical translational researcher in lymphoma, with a focus on novel immunotherapies and biomarkers. She holds a particular interest in tumor vaccine therapies and has developed vaccine trials for chronic myelogenous leukemia and for lymphoma. Through a laboratory collaboration with Richard Jones and William Matsui, she is also investigating the clinical utility of potential tumor stem cell targeting agents for lymphoma.
Education/Training:
1991-1995 A.B., Biology, Harvard University, Cambridge, Massachusetts
1995-1999 M.D., University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania
1999-2002 Internship and Residency in Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts
2002-2005 Fellowship in Hematology and Oncology, Johns Hopkins University, Baltimore, Maryland
Academic Positions:
2005-Present Assistant Professor of Oncology and Medicine, Johns Hopkins University, Baltimore, Maryland
Selected Publications
- Tuting T, Wilson CC, Martin D, Kasamon Y, Rowles J, Ma DI, Slingluff CL, Wagner SC, van der Brugeen P, Baar J, Lotze MT, Storkus WJ. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitr Enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-?. Journal of Immunology 1998; 160: 1139-1147.
- Kierstead LS, Ranieri E, Kasamon YL, Brusic V, Sidney J, Sette A, Slingluff CL Jr, Kirkwood JM, Storkus WJ. Gp100/pmel17 and tyrosinase encode multiple epitopes recognized by Th1-type CD4+ T cells. British Journal of Cancer 2001; 85: 1738-1745.
- Kasamon YL, Nguyen TN, Chan JA, Nascimento AF. EBV-associated lymphoma and chronic inflammatory demyelinating polyneuropathy in an adult without overt immunodeficiency. American Journal of Hematology 2002; 69: 289-293.
- Tatsumi T, Kierstead LS, Ranieri E, Gesualdo L, Schena FP, Finke JH, Bukowski RM, Brusic V, Sidney J, Sette A, Logan TF, Kasamon YL, Slingluff CL Jr, Kirkwood JM, Storkus WJ. MAGE-6 encodes HLA-DRß1*0401-presented epitopes recognized by CD4+ T cells from patients with melanoma or renal cell carcinoma. Clinical Cancer Research 2003; 9: 947-954.
- Kasamon YL, Wahl RL, Swinnen LJ. FDG-PET and high dose therapy for aggressive non-Hodgkin’s lymphoma: Toward a risk-adapted strategy. Current Opinion in Oncology 2004; 16: 100-105.
- Kasamon YL, Swinnen LJ. Treatment advances in adult Burkitt lymphoma and leukemia. Current Opinion in Oncology 2004; 16: 429-435.
- Kasamon YL, Jones RJ, Diehl LF, Nayer H, Borowitz MJ, Garrett-Mayer E, Ambinder RF, Abrams RA, Zhang Z, Flinn IW. Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma. Biology of Blood and Marrow Transplantation 2005; 11: 39-46.
- Kasamon YL, Jones RJ, Piantadosi S, Ambinder RF, Abrams RA, Borowitz MJ, Morrison C, Smith BD, Flinn IW. High-dose therapy and blood or marrow transplantation for non-Hodgkin’s lymphoma with central nervous system involvement. Biology of Blood and Marrow Transplantation 2005; 11: 93-100.
- Kasamon YL, Ambinder RF. AIDS-related primary central nervous system lymphoma. In press, Hematology/Oncology Clinics of North America 2005; 19: 665-687.
- Kasamon YL, Flinn IW, Grever MR, Diehl LF, Garrett-Mayer E, Goodman SN, Lucas MS, Byrd JC. Phase I Study of Low-Dose IL-2, Fludarabine, and Cyclophosphamide for Previously Untreated Indolent Lymphoma and Chronic Lymphocytic Leukemia: No Evidence of Cellular Immune Protection. Clinical Cancer Research 2005; 11: 8413-8417.
- Kasamon YL, Flinn IW, Grever MR, Diehl LF, Garrett-Mayer E, Goodman SN, Lucas MS, Byrd JC. Phase I study of low dose IL-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. Clinical Cancer Research 2005; 11: 8413-8417.
- Kasamon YL, Flinn IW, Grever MR, Diehl LF, Garrett-Mayer E, Goodman SN, Lucas MS, Byrd JC. Phase I study of low dose IL-2, fludarabine, and cyclophosphamide for previously untreated indolent lymphoma and chronic lymphocytic leukemia. Clinical Cancer Research 2005; 11: 8413-8417.
- Kasamon YL, Flinn IW. Management of symptomatic, untreated chronic lymphocytic leukemia. In press, Blood Reviews; Nov 9, 2006 [Epub ahead of print].
- Kasamon YL, Jones RJ, Wahl RL. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma. The Journal of Nuclear Medicine 2007; 48 (1 suppl): 19S-27S.
- Kasamon YL. Blood or marrow transplantation for mantle cell lymphoma. In press, Current Opinion in Oncology.
